ORIC Pharmaceuticals Inc
ORIC
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.12B
Close$
$0.39
96.3% downside
Current Fair Value
96.3% downsideOvervalued by 96.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.12 Billion |
|---|---|
| Enterprise Value | $1.07 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.47 |
| Beta | 1.01 |
| Outstanding Shares | 105,472,766 |
Return
| Return on Equity | -32.54% |
|---|---|
| Return on Assets | -30.96% |
| Return on Invested Capital | -34.88% |
Valuation & Multiples
| P/E Ratio | -7.53 |
|---|---|
| PEG | -39.37 |
| Price to Sales | - |
| Price to Book Ratio | 3.52 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.3 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-0.33
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.34
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 92.62% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.07%▼ 135.88% |
|---|---|
| Total Invested | $780,096▼ 99.95% |
| Investors Holding | 4▼ 181.00% |
ESG Score
No data
About ORIC Pharmaceuticals Inc
CEO: Jacob Chacko